Pacira Pharmaceuticals, Inc., a specialty pharmaceutical company, develops, manufactures, and commercializes proprietary pharmaceutical products primarily for use in hospitals and ambulatory surgery centers in the United States. It develops pharmaceutical products based on its proprietary DepoFoam drug delivery technology. The company's lead product includes, EXPAREL, a liposome injection of bupivacaine, an amide-type local anesthetic indicated for single-dose infiltration into the surgical site to produce postsurgical analgesia. The company was formerly known as Pacira, Inc. and changed its name to Pacira Pharmaceuticals, Inc. in October 2010. Pacira Pharmaceuticals, Inc. was founded in 2006 and is headquartered in Parsippany, New Jersey.
Industry, Sector and Symbol
Stock Exchange NASDAQ
Industry Pharmaceutical preparations
Sub-IndustryPharmaceuticals
SectorMedical
SymbolNASDAQ:PCRX
CUSIP69512710
Phone973-254-3560
Debt
Debt-to-Equity Ratio0.98
Current Ratio8.58
Quick Ratio7.79
Price-To-Earnings
Trailing P/E Ratio-81.03
Forward P/E Ratio-213.64
P/E GrowthN/A
Sales & Book Value
Annual Sales$286.63 million
Price / Sales6.72
Cash Flow$0.0599 per share
Price / Cash784.86
Book Value$6.89 per share
Price / Book6.82
Profitability
EPS (Most Recent Fiscal Year)($0.58)
Net Income$-42,610,000.00
Net Margins-3.64%
Return on Equity-0.39%
Return on Assets-0.17%
Miscellaneous
Employees489
Outstanding Shares40,960,000
Market Cap$1.97 billion
Pacira Pharmaceuticals (NASDAQ:PCRX) Frequently Asked Questions
What is Pacira Pharmaceuticals' stock symbol?
Pacira Pharmaceuticals trades on the NASDAQ under the ticker symbol "PCRX."
How were Pacira Pharmaceuticals' earnings last quarter?
Pacira Pharmaceuticals Inc (NASDAQ:PCRX) issued its earnings results on Thursday, August, 2nd. The company reported $0.24 earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.13) by $0.37. The company had revenue of $84.10 million for the quarter, compared to the consensus estimate of $77.53 million. Pacira Pharmaceuticals had a negative return on equity of 0.39% and a negative net margin of 3.64%. The firm's quarterly revenue was up 18.6% on a year-over-year basis. During the same quarter last year, the company earned ($0.11) EPS. View Pacira Pharmaceuticals' Earnings History.
When is Pacira Pharmaceuticals' next earnings date?
What price target have analysts set for PCRX?
19 Wall Street analysts have issued 12-month price targets for Pacira Pharmaceuticals' shares. Their predictions range from $27.00 to $80.00. On average, they expect Pacira Pharmaceuticals' stock price to reach $48.4118 in the next twelve months. This suggests a possible upside of 3.0% from the stock's current price. View Analyst Price Targets for Pacira Pharmaceuticals.
What is the consensus analysts' recommendation for Pacira Pharmaceuticals?
19 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Pacira Pharmaceuticals in the last year. There are currently 2 sell ratings, 8 hold ratings and 9 buy ratings for the stock, resulting in a consensus recommendation of "Hold." View Analyst Ratings for Pacira Pharmaceuticals.
What are Wall Street analysts saying about Pacira Pharmaceuticals stock?
Here are some recent quotes from research analysts about Pacira Pharmaceuticals stock:
- 1. According to Zacks Investment Research, "Pacira’s top line mainly comprises contribution from its marketed product-Exparel. It is making efforts to expand Exparel's label. In April 2018, the FDA approved Pacira’s sNDA seeking expansion of the Exparel label to include administration via nerve block for prolonged regional analgesia. However, the company is heavily dependent on Exparel for growth, which accounts for a significant chunk of its revenues. This is a concern for the company. Exparel also competes with well-established products for postsurgical pain management." (7/15/2018)
- 2. HC Wainwright analysts commented, "Valuation and risks. Our $48 12-month target is based on an average of our $55/share DCF (10% WACC discount rate; 1% terminal growth beyond 2024) and a $41/share P/E multiple derived valuation (30x fully-taxed 2020 EPS, or 1x PEG, discounted back)." (7/10/2018)
- 3. Mizuho analysts commented, "We switched from Symphony Health data last month, after a sizeable data restatement from the vendor rendered our prior estimates unreliable." (6/29/2018)
Who are some of Pacira Pharmaceuticals' key competitors?
Some companies that are related to Pacira Pharmaceuticals include Alnylam Pharmaceuticals (ALNY), Beigene (BGNE), Ionis Pharmaceuticals (IONS), Alkermes (ALKS), Catalent (CTLT), SAGE Therapeutics (SAGE), Amarin (AMRN), Dr.Reddy's Laboratories (RDY), Amneal Pharmaceuticals (AMRX), United Therapeutics (UTHR), GALAPAGOS NV/S (GLPG), Loxo Oncology (LOXO), FibroGen (FGEN), GW Pharmaceuticals PLC- (GWPH) and Ligand Pharmaceuticals (LGND).
Who are Pacira Pharmaceuticals' key executives?
Pacira Pharmaceuticals' management team includes the folowing people:
- Mr. David M. Stack, Chairman & CEO (Age 68)
- Mr. Charles A. Reinhart III, Chief Financial Officer (Age 57)
- Dr. Richard Scranton M.D., MPH, Chief Scientific Officer (Age 57)
- Ms. Kristen Williams, Chief Admin. Officer & Sec. (Age 44)
- Ms. Lauren Bullaro Riker, Principal Accounting Officer & VP of Fin. (Age 39)
Who are Pacira Pharmaceuticals' major shareholders?
Pacira Pharmaceuticals' stock is owned by many different of retail and institutional investors. Top institutional shareholders include Peregrine Capital Management LLC (0.55%), Legacy Capital Partners Inc. (0.12%), Mizuho Securities USA LLC (0.06%), Seven Eight Capital LP (0.02%) and Bouchey Financial Group Ltd (0.01%). Company insiders that own Pacira Pharmaceuticals stock include Charles A Reinhart III, David M Stack, James B Jones, James S Scibetta, Kristen Marie Williams, Lauren Bullaro Riker, Mark A Kronenfeld, Mark Froimson, Paul J Hastings, Richard Scranton and Scott Braunstein. View Institutional Ownership Trends for Pacira Pharmaceuticals.
Which major investors are selling Pacira Pharmaceuticals stock?
PCRX stock was sold by a variety of institutional investors in the last quarter, including Peregrine Capital Management LLC and Legacy Capital Partners Inc.. Company insiders that have sold Pacira Pharmaceuticals company stock in the last year include Charles A Reinhart III, David M Stack, James B Jones, Kristen Marie Williams, Lauren Bullaro Riker, Paul J Hastings and Richard Scranton. View Insider Buying and Selling for Pacira Pharmaceuticals.
Which major investors are buying Pacira Pharmaceuticals stock?
PCRX stock was acquired by a variety of institutional investors in the last quarter, including Mizuho Securities USA LLC, Seven Eight Capital LP and Bouchey Financial Group Ltd. Company insiders that have bought Pacira Pharmaceuticals stock in the last two years include Mark A Kronenfeld and Mark Froimson. View Insider Buying and Selling for Pacira Pharmaceuticals.
How do I buy shares of Pacira Pharmaceuticals?
Shares of PCRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab.
What is Pacira Pharmaceuticals' stock price today?
One share of PCRX stock can currently be purchased for approximately $47.00.
How big of a company is Pacira Pharmaceuticals?
Pacira Pharmaceuticals has a market capitalization of $1.97 billion and generates $286.63 million in revenue each year. The company earns $-42,610,000.00 in net income (profit) each year or ($0.58) on an earnings per share basis. Pacira Pharmaceuticals employs 489 workers across the globe.
What is Pacira Pharmaceuticals' official website?
How can I contact Pacira Pharmaceuticals?
Pacira Pharmaceuticals' mailing address is 5 SYLVAN WAY SUITE 300, PARSIPPANY NJ, 07054. The company can be reached via phone at 973-254-3560 or via email at [email protected]
MarketBeat Community Rating for Pacira Pharmaceuticals (NASDAQ PCRX)
MarketBeat's community ratings are surveys of what our community members think about Pacira Pharmaceuticals and other stocks. Vote "Outperform" if you believe PCRX will outperform the S&P 500 over the long term. Vote "Underperform" if you believe PCRX will underperform the S&P 500 over the long term. You may vote once every thirty days.
